drugset / Trial / NCT00424034

A Study of GSK1325760A in Healthy Japanese Subjects

NCT00424034

Phase 1 Completed 32 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindTreatment

Summary

To investigate the safety, tolerability, pharmacokinetics and the effect of food on pharmacokinetics after single oral administrations of GSK1325760A

Timeline

Start
2007-01
Primary completion
2007-02
Completion
2007-02

Drugs

EvaluationDrugModalityDoseRoute
Subject Ambrisentan Small molecule Oral

Indications

No indication recorded.